Patients with stage III breast cancer can have a survival time of 3 or 5 years after surgery if they have timely and effective treatment, and the survival rate can reach about 50%. Because patients with stage III breast cancer usually have a combination of axillary lymph node fusion and metastasis, neoadjuvant therapy should be performed before surgery to be able to reduce the clinical stage and improve the cure rate and survival time of the tumor. Patients with advanced stage can have a survival rate of 20-30% and also require systemic radiotherapy, chemotherapy or palliative surgical excision. Especially for triple-negative breast cancer, it is easy to have local recurrence or distant metastasis within 1-2 years after surgery, chemotherapy can also significantly reduce the chance of recurrence.